Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus dose-dense temozolomide for first recurrent or progressive glioblastoma after Stupp regimen
ChiCTR2000037494Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and temozolomide in glioblastoma (GBM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: progression-free survival. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
anlotinibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000037494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037494.